| EQIX |
Report |
Q2'26 AFFO/share |
BEAT |
pred ~$11.05 vs. cons ~$10.85 |
MEDIUM |
| EQIX |
Report |
Q2'26 Revenue (incl. Hampton xScale) |
IN-LINE |
pred ~$2.60B vs. cons ~$2.59B |
MEDIUM |
| EQIX |
Report |
Q2'26 Adj. EBITDA |
IN-LINE |
pred ~$1.375B vs. cons ~$1.370B |
MEDIUM |
| EQIX |
Guide |
FY26 Revenue guide |
UNCHANGED |
guide ~$10.19B vs. cons ~$10.21B (FY2026, midpoint) |
MEDIUM |
| EQIX |
Guide |
FY26 AFFO/share guide |
BETTER |
guide ~$43.0 vs. cons ~$42.75 (FY2026, midpoint) |
LOW |
| EQIX |
Guide |
FY26 Adj. EBITDA margin guide |
UNCHANGED |
guide ~51% vs. cons ~51% (FY2026) |
MEDIUM |
| EQIX |
Guide |
Q3'26 Revenue guide |
UNKNOWN |
guide ~$2.63B vs. cons ~$2.64B (Q3 2026) |
LOW |
| EQIX |
Guide |
MRR growth (norm. cc) |
BETTER |
guide/print ~+10% vs. cons ~+10% (Q2 2026, 3rd straight double-digit) |
MEDIUM |
| EQIX |
Guide |
Hampton xScale lease signing |
UNKNOWN |
pred ~$80M rev/$0.65 AFFO booked vs. cons assumes signed (Q2 2026) |
LOW |
| EQIX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| EQIX |
Return |
5-day cumulative residual |
-3.0% (FADE) |
Expectations are elevated after a ~35% YTD run and a late-July DLR-sympathy pop to ~$1,084 that already faded to ~$1,035 into the print; beta to SPY is low (~0.4) so most of the move is idiosyncratic. A beat/small guide-bump is largely telegraphed and front-loaded from the Q1 raise, so it reads as a 'quality-of-momentum' quarter. Out-period math is unfavorable: the revenue inflection is back-half-2027 loaded, capex sits at the top end (~$4.1B) with a rising net-interest AFFO headwind (~$200M in 2026) and the flagged ~$7 investment drag, plus overhangs from the new CFO's first full call, Jon Lin's departure, and Hampton-timing credibility risk. Even on a headline beat, sell-side AFFO/share revisions get capped by the interest/capex drag, pulling estimates and the stock lower over 5 days. |
LOW |